ISARIC has been committed to provide a wide breadth of COVID-19 clinical research resources since the beginning of the outbreak. These resources are fully adaptable and completely free to use
The tools below aim to cover a range of tiers, suitable for different needs:
- Data collection only
- Contributing clinical data
- Research protocols
- Guidance to start your study
- ISARIC’s affiliated studies
Tile subhead - Publications and Clinical data reports stemmed from the ISARIC COVID-19 clinical data platform.
Tile subhead - Collection of standardised clinical data.
Tile subhead - Modules to be used in addition to the Core or RAPID COVID-19 CRFs.
Tile subhead - Stand alone CRF for children and adolescents.
Tile subhead - Secure data capture system that standardises global data on COVID-19.
Tile subhead - Access ISARIC's data to generate and disseminate evidence.
Tile subhead - Data analysis frequently asked questions.
Tile subhead - Current data research analyses.
Tile subhead - Sites currently contributing to the clinical data platform.
Tile subhead - ISARIC/WHO protocol for standardised clinical data collection.
Tile subhead - Follow-up clinical data collection
Tile subhead - Survey for the follow-up of patients with confirmed COVID-19.
Tile subhead - Paediatric protocol and survey for the follow-up of COVID-19 patients.
Tile subhead - Guidance on the Global Clinical Characterisation Protocol.
Tile subhead - High quality rapid evidence synthesis for use in COVID-19 research.
Tile subhead - Clinical data collection with the aims of building a research or study
Visit this section to find ISARIC’s articles, studies and more.
Women under 50 and people who experienced severe disease had worse long-term outcomes following hospitalisation with COVID-19.
ISARIC, supported by the UK Coronavirus Immunology Consortium (UK-CIC), has identified new biomarkers of inflammation that both indicate the severity of COVID-19 and distinguish it from severe influenza.
The Lancet Infectious Diseases published the GloPID-R and ISARIC Long COVID Forum Working Group’ letter, describing the content and discussions of the Long COVID Forum which took place on 9-10 December 2020.